Clinical Trial Update: Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sunitinib in patients with chronic myelomonocytic leukemia and myelodysplastic syndromes has completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• De Novo Myelodysplastic Syndromes
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2014-09-01